At the end of today’s hearings, an FDA advisory panel will issue recommendations about whether manufacturers of electroconvulsive devices must put their devices to rigorous safety tests or whether they should be reclassified from Class III (high risk) to Class II (moderate . . . Continue reading →
Placebo Effect
Why Psychoterapies Never Get Better
The latest psychotherapy fad is "cybertherapy embraces escapism and the mechanized techniques of "virtual reality." It has been given a veneer of legitimacy by a prominent article in the New York Times "Science" section. Continue reading →
Glaxo Is Testing Paxil on 7-Year-Olds Despite Well Known Suicide Risks
Despite the fact that children may be at highest risk of antidepressant-induced suicide, GlaxoSmithKline is testing Paxil on 7 to 18 year old Japanese children. Continue reading →
Another Psych Drug Demonstrated to be USELESS / HARMFUL_Yale /Columbia
"the first-ever randomized, placebo-controlled trial for the alleviation of post-traumatic stress disorder (PTSD)" reports: "we found that it really offered patients no benefits of any symptoms." [1] Continue reading →
Separating the Facts from the Propaganda_Latest Findings of Depression Study
Today's news report circulated by the media about the negative findings of a much touted, but uncontrolled observational study of depression (STAR*D) promotes the business interests of SSRI antidepressant drug manufacturers.
Commonly recommended Treatments found Worthless
Commonly recommended Treatments found Worthless Wed, 19 Mar 2003 Independent analyses of the clinical studies upon which widely recommended drug treatments have been based, have now been found to be fatally faulty, and the drugs are deemed worthless. An analysis of 83 . . . Continue reading →
Reply to the ACNP’s Report on SSRI and Suicidal Behavior in Children – Leo
Reply to the American College of Neuropharmacology’s Report on SSRI and Suicidal Behavior in Children Jonathan Leo, Ph.D. Introduction The American College of Neuropsychopharmacology (ACNP) recently released an Executive Summary from its Task Force on SSRIs and Suicidal Behavior. The task force . . . Continue reading →
Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ
Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ Fri, 29 Jul 2005 The Wall Street Journal uncritically reported: “The results of the largest studies ever conducted of depression and schizophrenia will be released in coming months, potentially . . . Continue reading →
Are SSRIs and Atypical Antidepressants Safe/ Effective for Children/ Adolescents/ Neonates?
Are SSRIs and Atypical Antidepressants Safe / Effective for Children / Adolescents/ Neonates? Wed, 2 Mar 2005 The American psychiatric establishment continues to operate within a “head in the sand” culture of denial when confronted with compelling evidence that has been scientifically . . . Continue reading →
ADHD drug Cylert withdrawn from market due to Liver Toxicity
ADHD drug – Cylert withdrawn from market due to Liver Toxicity, a Major Risk of Psychotropic Drugs Tue, October 25, 2005 The FDA announced that another drug prescribed for ADHD–Cylert–was removed from the US market for safety reasons. On September 25, 2005, . . . Continue reading →
Pharma’s Pervasive Influence Corrupts Medicine both sides of Atlantic
Pharma’s Pervasive Influence Corrupts Medicine both sides of Atlantic Tue, 4 Oct 2005 The focus of criticism in medicine has shifted from cost and barriers to access to treatments to an examination of the safety and benefit of current treatments. The pharmaceutical . . . Continue reading →
Antidepressant Use in Children Soars Despite Efficacy Doubts – Washington Post
Antidepressant Use in Children Soars Despite Efficacy Doubts – Washington Post Mon, 19 Apr 2004 A front page article by Shankar Vedantam in The Washington Post examines the soaring increase in the antidepressant drug prescriptions for children, noting: “The explosion in antidepressant . . . Continue reading →